AAO: Sequential nonarteritic anterior ischemic optic neuropathy occurs earlier with GLP-1 receptor agonist exposure
For patients with nonarteritic anterior ischemic optic neuropathy (NAION), glucagon-like peptide-1 (GLP-1) receptor agonist exposure is associated with earlier sequential NAION, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held Oct. 9 to 12 in New Orleans.
A recent study presented at the American Academy of Ophthalmology meeting in New Orleans has found a link between exposure to GLP-1 receptor agonist drugs and earlier sequential nonarteritic anterior ischemic optic neuropathy (NAION) in patients. The study, conducted by Ashley Tin and colleagues at the Carle Illinois College of Medicine, examined whether GLP-1 receptor agonist exposure is associated with a higher likelihood of early NAION.
The researchers compared early (one to six months) versus late (36 to 60 months) NAION events in 1,440 GLP-1 receptor agonist users and 20,713 nonusers. They found that 69.5% of events occurred within six months in GLP-1 receptor agonist users, compared to 52% in nonusers (relative risk, 2.63). This higher concentration of early events was consistent across different eras of GLP-1 receptor agonist use.
The study also revealed that GLP-1 receptor agonist users had higher hemoglobin A1c levels compared to nonusers. Tin noted that the findings align with clinical observations that prompted the study, but the large database analysis provided a striking confirmation of the clinical impression. The researchers were not surprised by the results, as the association makes sense, but they emphasize the need for further investigation into the relationship between GLP-1 receptor agonist exposure and earlier sequential NAION.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
